One statistic captures the scale of what is happening in pharmacology. In 2025, Eli Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, generated $36.5 billion in sales, making it the highest-grossing drug molecule in history. It surpassed Keytruda, Merck’s blockbuster cancer immunotherapy, which had held the title for years.
Combined with Novo Nordisk’s semaglutide franchise (Ozempic, Wegovy, Rybelsus), which pulled in $31.2 billion, the GLP-1 receptor agonist class now represents a roughly $70 billion annual market. Projections from investment banks place it between $156 billion and $268 billion by 2030. Eli Lilly itself went from outside the top 10 pharmaceutical companies by revenue to number one in a single year, largely on the strength of a single drug class.
This is not a story about one drug. It is a story about a mechanism of action that appears to touch nearly every organ system in the body, that is being pursued by more than 60 companies with more than 135 candidates in clinical trials, and that may, the evidence is preliminary but growing, modulate the rate of biological aging itself.
GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells after eating. It binds to receptors in the pancreas to stimulate insulin secretion and suppress glucagon release, but that is the simplest part of its biology. GLP-1 receptors are also expressed in the brain, heart, blood vessels, kidneys, liver, stomach, and adipose tissue. The receptor’s distributed expression is the reason GLP-1 drugs produce effects far beyond glucose control.
The first GLP-1 receptor agonist, exenatide (Byetta), was approved in 2005. It was derived from Gila monster venom and required twice-daily injections. The second generation, led by semaglutide, used structural modifications to extend the half-life to a once-weekly injection. The third generation, exemplified by tirzepatide, added agonism at the GIP (glucose-dependent insulinotropic polypeptide) receptor, a dual mechanism that amplified weight loss from approximately 15 percent with semaglutide to 22 percent with tirzepatide.
The fourth wave is already here.
The Combination Revolution
The core insight driving current GLP-1 development is that co-agonism at related receptors produces synergistic effects. There are four main combination strategies, each with distinct advantages.
GLP-1 + GIP: The Standard Bearer
Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrated that adding GIP signaling roughly doubled the weight loss of GLP-1 agonism alone. GIP was initially thought to be a counterproductive target because it stimulates insulin secretion similarly to GLP-1, but it turns out that GIP agonism also affects lipid metabolism and fat distribution in ways that complement GLP-1. The result is approximately 22.5 percent mean weight loss, putting tirzepatide in a class of its own among approved drugs, until the triple agonists arrive.
GLP-1 + Glucagon: Energy Expenditure
Boehringer Ingelheim and Zealand Pharma’s survodutide adds glucagon receptor agonism to GLP-1. Glucagon increases energy expenditure by promoting lipolysis and thermogenesis, which means weight loss from the combination comes partly from burning more calories, not just eating less. Survodutide has also shown strong signals in MASH (metabolic dysfunction-associated steatohepatitis), reducing liver fat independent of weight loss. In Phase 2 trials, it produced 16.6 percent weight loss at 76 weeks, with Phase 3 projected to report around 2028.
GLP-1 + Amylin: Two Satiety Pathways
Amylin is a pancreatic hormone that acts on the area postrema in the brainstem to induce satiety. Semaglutide works primarily through hypothalamic pathways. Because these two pathways are distinct, their effects are additive. Novo Nordisk’s combination, cagrilintide (an amylin analogue) plus semaglutide, called CagriSema, produced approximately 23 percent weight loss in Phase 2, with an NDA filed in December 2025.
Novo is also developing amycretin, a single-molecule GLP-1/amylin dual agonist, which showed approximately 22 percent weight loss in early trials and entered Phase 3 in early 2026.
Triple Agonists: Targeting All Three Pathways
Eli Lilly’s retatrutide is the furthest along of the triple agonists, combining GLP-1, GIP, and glucagon receptor agonism in a single molecule. In the TRIUMPH-4 trial, retatrutide achieved 28.7 percent mean weight loss, approaching the results of bariatric surgery. In patients with a BMI of 35 or higher, extended dosing produced up to 30.3 percent weight loss at 104 weeks.
Viking Therapeutics is developing VK2735, a dual GLP-1/GIP agonist available in both injectable and oral forms. The oral formulation produced 12.2 percent weight loss at 13 weeks in Phase 2, a strong early signal for an oral agent.
The Pipeline: 60 Companies, 135+ Candidates
The competitive landscape has shifted dramatically. In 2020, essentially two companies, Novo Nordisk and Eli Lilly, dominated GLP-1 development. By 2026, more than 60 companies have active programs, with candidates at every stage of development.
Approved in 2025-2026:
- Wegovy HD (semaglutide 7.2 mg): March 2026, 20.7 percent weight loss
- Wegovy pill (oral semaglutide 25 mg): December 2025, first oral GLP-1 for weight loss
- Foundayo (orforglipron): April 2026, Lilly’s oral small-molecule GLP-1, 12.4 percent weight loss, priced at $149 per month
Late-stage candidates awaiting decisions:
- CagriSema: NDA filed December 2025, approximately 23 percent weight loss
- Retatrutide: Phase 3 complete, filing expected late 2026 or early 2027
Notable Phase 2 programs:
- MariTide (Amgen): GLP-1 agonist combined with a GIP receptor antagonist, a novel approach that achieved approximately 20 percent weight loss with monthly dosing
- Survodutide (BI/Zealand): GLP-1/glucagon dual agonist with strong MASH data
- VK2735 (Viking): Dual GLP-1/GIP, oral formulation
- Aleniglipron (Structure Therapeutics): Oral small-molecule GLP-1, 16.3 percent weight loss in Phase 2, outperforming orforglipron on early data
- Petrelintide (Zealand/Roche): Amylin analogue with 10.7 percent weight loss and near-placebo tolerability; Roche paid $1.65 billion for access
The major challengers also include Pfizer (danuglipron and the Metsera pipeline), Roche (Carmot acquisition for $2.7 billion), AstraZeneca, Merck (efinopegdutide), and a wave of Chinese and Korean biotechs including Kailera Therapeutics, Innovent Biologics, Hanmi Pharmaceutical, and Sciwind Biosciences.
Beyond Diabetes and Obesity
The most remarkable feature of GLP-1 drugs is the breadth of their effects beyond the indications for which they were developed.
Cardiovascular disease: The SELECT trial, published in 2024, showed that semaglutide reduced major adverse cardiovascular events by 20 percent, and the benefit was independent of weight loss, suggesting direct vascular effects. This has transformed the perception of GLP-1 drugs from metabolic agents to cardiovascular therapies.
Sleep apnea: Zepbound became the first FDA-approved medication for obstructive sleep apnea in December 2024. The SURMOUNT-OSA trial showed that tirzepatide reduced the apnea-hypopnea index by 25 to 30 events per hour, enough to resolve the condition in a significant subset of patients.
MASH: Multiple programs are targeting MASH. Semaglutide received approval for MASH in 2025; survodutide has shown particularly promising liver fibrosis data.
Chronic kidney disease: The FLOW trial (2024) demonstrated that semaglutide reduced the risk of major kidney disease events by 24 percent in patients with type 2 diabetes and chronic kidney disease. Ozempic received FDA approval for CKD in 2025.
Addiction: A Washington University study of 606,000 veterans with substance use disorders found that GLP-1 drugs reduced the risk of overdose and death across all substance categories, alcohol, opioids, cannabis, stimulants. The effect appears to be mediated through the brain’s reward circuitry, reducing craving. Phase 3 trials specifically for alcohol use disorder are now underway, including the VA Cooperative Study CRAVE trial for semaglutide.
Neuroprotection, a mixed picture: The most eagerly anticipated indication, Alzheimer’s disease, produced a disappointing result. In November 2025, the EVOKE and EVOKE+ trials found that oral semaglutide 14 mg did not slow cognitive decline in 3,808 patients with early Alzheimer’s. Biomarkers improved, but clinical function did not. The extension phase was terminated.
Parkinson’s disease, however, has shown more promise. A Phase 2 trial of lixisenatide (a short-acting GLP-1 agonist) published in the New England Journal of Medicine in 2024 found a 3.08-point motor improvement in patients with early Parkinson’s, a modest but clinically detectable difference. Larger trials are needed.
Observational studies have been more encouraging for dementia broadly. A Danish registry study found that GLP-1 users had a 53 percent reduced risk of dementia, and a separate analysis found that dulaglutide was associated with a 14 percent reduction in cognitive decline.
The $100 Billion Manufacturing Buildout
The GLP-1 supply crisis of 2023-2025, when millions of patients could not fill prescriptions, has triggered an unprecedented manufacturing expansion.
Novo Nordisk spent $9 billion on capital expenditures in 2025 alone, acquired Catalent for $11 billion to obtain three fill-finish facilities, and is building a $4.1 billion plant in North Carolina. Eli Lilly has committed more than $50 billion in manufacturing investment since 2020, including a $6.5 billion facility in Houston for orforglipron, a $5.3 billion site in Indiana for tirzepatide active pharmaceutical ingredient, and a $3.5 billion plant in Pennsylvania for retatrutide.
The race to build capacity reflects a strategic calculation: oral small-molecule GLP-1s like orforglipron and aleniglipron can be manufactured far more cheaply than injected peptides, potentially collapsing the cost structure of the market.
Foundayo, Lilly’s oral orforglipron for weight loss, launched at $149 per month, a dramatic discount from the $1,000-plus list prices of branded injectables. This has already forced pricing pressure across the class.
Can We Fix the Obesity Epidemic?
The data are encouraging but sobering. The SELECT trial found that semaglutide reduced progression to type 2 diabetes by 73 percent over four years, a preventive effect that, if sustained, would be among the largest ever demonstrated for any drug. US bariatric surgery volume has dropped 42 percent since 2019 as medical therapy has improved.
But real-world adherence is a major problem. Approximately 50 percent of patients stop taking GLP-1 drugs within one year, with gastrointestinal side effects, nausea, vomiting, diarrhea, being the most common reason. Weight regain after discontinuation is nearly universal, and the drug class does not address the structural drivers of obesity: food environment, socioeconomic factors, and the biology of weight regulation beyond the incretin system.
US obesity rates may be plateauing, but they are not declining rapidly. The drugs are most effective for the patients who can tolerate them and afford them long-term, a subset of a subset.
The Longevity Connection
In June 2026, a randomized controlled trial from UC San Diego published in Nature Communications provided the clearest evidence yet that semaglutide slows biological aging. The drug reduced the DunedinPACE epigenetic clock by 9 percent, a measure of the pace of biological aging, and improved the PCGrimAge clock, which estimates mortality risk. The effects were partially independent of weight loss, suggesting direct anti-aging mechanisms that may include reduced inflammation (C-reactive protein dropped by 40 percent), improved mitochondrial function, and modulation of cellular senescence pathways.
A Nature Biotechnology editorial in November 2025 formally posed the question: “Are GLP-1s the first longevity drugs?” Researchers from Novo Nordisk and Lilly have both published on the possibility, and Novo has extended the SELECT trial into an open-label extension called SELECT-LIFE specifically to study long-term survival outcomes.
The caveats are important. No lifespan extension trial in healthy individuals exists. The evidence for age-related disease prevention is strongest for cardiovascular and kidney disease, conditions common in people with metabolic syndrome, and much weaker for neurodegenerative diseases. The question of whether GLP-1s extend lifespan in metabolically healthy individuals remains entirely open.
The Economic Transformation
The macroeconomic implications are staggering. The USC Schaeffer Center estimates that widespread GLP-1 use could save Medicare $245 billion over 10 years through reduced cardiovascular, kidney, and diabetes complications. The global obesity-attributable healthcare expenditure could reach $9.1 trillion over the next decade without effective intervention.
Consumer behavior is already shifting. A 2025 analysis found that households with a GLP-1 prescription reduced food spending by 5.5 percent, with the largest cuts in ultra-processed foods, which dropped 11 percent. The restaurant industry, packaged food companies, and alcohol producers are all adjusting their projections.
Medicare coverage for obesity medications, historically excluded by law, is expanding in mid-2026 under the GENEROUS model, which would make GLP-1s available to millions of additional beneficiaries at approximately $50 per month copay. This represents a fundamental shift in US health policy.
What This Means for Humanity
The GLP-1 revolution poses a question that the pharmaceutical industry has not had to confront since the development of statins: what happens when a drug class affects the most prevalent chronic diseases in the developed world simultaneously?
The honest answer is that we do not know. A world in which a substantial fraction of the adult population takes a medication that reduces calorie intake by 20 percent, improves cardiovascular and kidney outcomes independent of weight, reduces inflammation, and may slow biological aging is a world whose health trajectory is difficult to model.
The risks are equally uncharted. The muscle loss associated with GLP-1-induced weight loss, 25 to 40 percent of lost weight comes from lean mass, is a concern for aging populations, where sarcopenia is already a major cause of frailty. The gastrointestinal side effects, while not dangerous, are severe enough to cause half of patients to discontinue treatment. And the phenomenon of weight regain after discontinuation, nearly universal, often with partial overshoot, means that for many patients, these are lifetime medications.
The WHO added GLP-1s to its Essential Medicines List for diabetes in December 2025. The first global guideline recommending GLP-1s for obesity followed. But access remains deeply unequal: these drugs are available to patients in wealthy countries with insurance coverage, and largely unavailable to the rest of the world.
Whether GLP-1 receptor agonists become a turning point in human health depends not on the science, the science is extraordinary, but on whether society can solve the problems of adherence, cost, access, and long-term safety. The pharmacological foundation is being built now. The rest will take a generation to work out.